

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE ON THE GRANT OF CHINA INVENTION PATENTS RELATED TO OSEMITAMAB (TST001) AND ITS COMPANION DIAGNOSTIC ANTIBODY

This announcement is made by Transcenta Holding Limited (the **“Company”**, together with its subsidiaries, the **“Group”**) on a voluntary basis to inform the shareholders and potential investors of the Company of its latest business development. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus of the Company dated September 14, 2021.

The board of directors of the Company (the **“Board”**) is pleased to announce that the invention patent application titled “Anti-CLDN18.2 Antibodies and Diagnostic Uses Thereof” (Application No.: CN202180041601.5) filed by Suzhou Transcenta Therapeutics Co., Ltd. (蘇州創勝醫藥集團有限公司) (**“Suzhou Transcenta”**), a wholly-owned subsidiary of the Company, has been granted an invention patent by the China National Intellectual Property Administration (the **“CNIPA”**), with the grant announcement number CN115836090B and the grant announcement date of September 25, 2026 (the **“Patent”**).

The Patent covers the anti-CLDN18.2 antibodies independently developed by the Group and their diagnostic use for detecting CLDN18.2 expression, and the relevant antibody is the proprietary Claudin18.2 antibody developed by the Group for the development of the companion diagnostic test of osemitamab (TST001). The Group continues to collaborate with Agilent Technologies, a global leader in companion diagnostic development, to advance the development of the Claudin18.2 companion diagnostic (**“CDx”**) in support of TranStar301, the global Phase III pivotal trial of osemitamab (TST001) in combination with immune checkpoint inhibitor and chemotherapy as first-line treatment for patients with Claudin18.2-expressing locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Previously, on August 2, 2024, Suzhou Transcenta was granted an invention patent by the CNIPA titled “Novel Anti-CLDN18.2 Antibodies” (grant announcement number: CN114630840B). In addition, patents related to osemitamab (TST001) have also been granted by the Federal Service for Intellectual Property of the Russian Federation and the Intellectual Property Department of Hong Kong. The Board believes that the grant of the Patent provides a crucial foundation for the Group’s intellectual property protection around Claudin18.2 and its CDx development, further strengthens the intellectual property position of osemitamab (TST001), and supports its precision medicine strategy, clinical development as well as future registration and commercialization in China.

Osemitamab (TST001), the Company's key program, is a high affinity humanized anti-Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (“**ADCC**”). The initiation of the global Phase III registrational trial (TranStar301) of osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy as first-line treatment for Claudin18.2-expressing gastric or gastroesophageal junction adenocarcinoma has been approved by the U.S. Food and Drug Administration (the “**FDA**”), the Center for Drug Evaluation of the National Medical Products Administration of China and the Ministry of Food and Drug Safety of Korea. Osemitamab (TST001) has been granted Orphan Drug Designation by the FDA for the treatment of gastric or gastroesophageal junction adenocarcinoma and pancreatic cancer.

By Order of the Board
Transcenta Holding Limited
Xueming Qian

Executive Director, Chairman and Chief Executive Officer

Hong Kong, October 12, 2026

As at the date of this announcement, the Board comprises (i) Dr. Xueming Qian as executive Director, chairman and chief executive officer; (ii) Dr. Li Xu and Dr. Han Sen Xu as non-executive Directors; and (iii) Mr. Jiasong Tang, Ms. Helen Wei Chen and Prof. Genhong Cheng as independent non-executive Directors.